Annuncio pubblicitario
Italia markets close in 15 minutes

  • FTSE MIB

    33.904,18
    +22,68 (+0,07%)
     

  • Dow Jones

    37.959,67
    +184,29 (+0,49%)
     

  • Nasdaq

    15.463,90
    -137,60 (-0,88%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    83,39
    +0,66 (+0,80%)
     

  • Bitcoin EUR

    60.507,30
    +533,38 (+0,89%)
     

  • CMC Crypto 200

    1.374,09
    +61,46 (+4,92%)
     

  • Oro

    2.407,70
    +9,70 (+0,40%)
     

  • EUR/USD

    1,0669
    +0,0023 (+0,21%)
     

  • S&P 500

    5.000,46
    -10,66 (-0,21%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.920,55
    -16,02 (-0,32%)
     

  • EUR/GBP

    0,8587
    +0,0032 (+0,37%)
     

  • EUR/CHF

    0,9694
    -0,0016 (-0,17%)
     

  • EUR/CAD

    1,4641
    -0,0009 (-0,06%)
     

Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics, Inc.
·1 minuto per la lettura
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT.

The webcast of the presentation will be accessible via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/, and an archived version will be made available for 90 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader (MGD) medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and MGD product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection, and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com.

Investors
Shai Biran, Monte Rosa Therapeutics
ir@monterosatx.com

Media
Dan Budwick, 1AB
dan@1abmedia.com